269 related articles for article (PubMed ID: 29903850)
1. Long-term survival in recurrent adrenocortical cancer.
Shuayb M; Das A; Uddin MN
BMJ Support Palliat Care; 2019 Mar; 9(1):47-50. PubMed ID: 29903850
[TBL] [Abstract][Full Text] [Related]
2. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, treatment and outcome of adrenocortical cancer.
Mihai R
Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
Payabyab EC; Balasubramaniam S; Edgerly M; Velarde M; Merino MJ; Venkatesan AM; Leuva H; Litman T; Bates SE; Fojo T
Clin Cancer Res; 2016 Oct; 22(20):4989-5000. PubMed ID: 27742785
[TBL] [Abstract][Full Text] [Related]
5. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
6. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
Tierney JF; Chivukula SV; Poirier J; Pappas SG; Schadde E; Hertl M; Kebebew E; Keutgen X
J Clin Endocrinol Metab; 2019 Dec; 104(12):5948-5956. PubMed ID: 31361313
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
8. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
9. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
10. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
Taza F; Chovanec M; Hahn N; Albany C
Clin Genitourin Cancer; 2017 Oct; 15(5):e893-e895. PubMed ID: 28606737
[No Abstract] [Full Text] [Related]
12. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
Bronswijk MJH; Laenen A; Bechter OE
Neoplasma; 2020 Jan; 67(1):209-213. PubMed ID: 31777255
[TBL] [Abstract][Full Text] [Related]
14. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
Sasaki S
Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
[TBL] [Abstract][Full Text] [Related]
15. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
16. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
17. Pediatric adrenocortical carcinoma.
Ilanchezhian M; Varghese DG; Glod JW; Reilly KM; Widemann BC; Pommier Y; Kaplan RN; Del Rivero J
Front Endocrinol (Lausanne); 2022; 13():961650. PubMed ID: 36387865
[TBL] [Abstract][Full Text] [Related]
18. [Adrenocortical carcinoma and its treatment].
Tupikowski W; Bednarek-Tupikowska G; Florczak A
Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
[TBL] [Abstract][Full Text] [Related]
19. Adrenocortical cancer treatment.
Patalano A; Brancato V; Mantero F
Horm Res; 2009 Jan; 71 Suppl 1():99-104. PubMed ID: 19153517
[TBL] [Abstract][Full Text] [Related]
20. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
